Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.93 |
| ▸ | RAB9A | P51151 | 2/20 | 0.93 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515973 | 0.81 | NPC1 (0.70) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20374588 | 0.81 | NPC1 (0.70) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20392028 | 0.81 | NPC1 (0.69) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20358372 | 0.81 | NPC1 (0.69) | NPC1RAB9ANCOA1NCOA3HPGD | |
| Biphenyl SCHEMBL28033347 | 0.79 | NPC1 (0.67) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20392114 | 0.79 | NPC1 (0.66) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20370323 | 0.79 | NPC1 (0.70) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL27597469 | 0.79 | NPC1 (0.61) | NPC1RAB9ANCOA1NCOA3HPGD | |
| SCHEMBL20374432 | 0.79 | NPC1 (0.63) | NPC1RAB9AHPGDLMNASMN1; SMN2 | |
| SCHEMBL20370326 | 0.78 | NPC1 (0.62) | NPC1RAB9ANCOA1NCOA3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509418-B2 | Chromophoric compounds and UV-absorbing compositions | LYGG CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250270164-A1 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | LYGG CORPORATION | 2025-08-28 | — | — | US | disclosed |
| US-20250074861-A1 | Anticonvulsant Compounds | OWEN BARRY PHARMACEUTICALS INC (CA) | 2025-03-06 | — | — | US | disclosed |
| US-11952338-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2024-04-09 | — | — | US | disclosed |
| US-11345652-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS (CA) | 2022-05-31 | — | — | US | disclosed |
| US-11345652-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS (CA) | 2022-05-31 | — | — | US | disclosed |
| US-20210017116-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2021-01-21 | — | — | US | disclosed |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-05-14 | — | — | US | disclosed |
| US-10556853-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| WO-2018129609-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-19 | — | — | WO | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
| US-6060484-A | Anti-viral method | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1997041846-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806205-A2 | Urea, thiourea and guanidine compounds and their use as anti-viral agents | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270164-A1 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | ERCC1, TYR, ERCC5 | NPC1 1517/4885RAB9A 2211/4885NCOA1 652/4885 |
| US-11952338-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-12509418-B2 | Chromophoric compounds and UV-absorbing compositions | LBR, ERCC1, MC1R | NPC1 968/4885RAB9A 2940/4885NCOA1 340/4885 |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-20210017116-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-11345652-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-20250074861-A1 | Anticonvulsant Compounds | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
| US-10556853-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | NPC1 1283/4885RAB9A 3217/4885NCOA1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.